Thermo Fisher Bioproduction Insights

  1. Select The Best Analyte: A Guide To Effective Mycoplasma Testing 9/24/2025

    As you build a Mycoplasma testing strategy to ensure drug safety, there are three analyte types to choose from: live Mycoplasma, RNA, and genomic DNA, each offering distinct advantages.

  2. A Paradigm Shift From Glass Benchtop Bioreactors 8/14/2025

    Learn how a bench-scale single-use bioreactor offers process development advantages over traditional glass systems, including higher efficiency, increased productivity, and enhanced sustainability.

  3. 5 Reasons To Reimagine Scalability With A Single-Use Bioreactor (S.U.B.) 8/14/2025

    Unlock the power of single-use bioreactors with a scalable design that streamlines your process from development to production, while also supporting sustainability goals.

  4. Scalability From 5L To 50L Using The DynaDrive Single-Use Bioreactor 8/14/2025

    Maintaining a consistent bioprocess when scaling from 5 L to 50 L is achievable. This study shows how to successfully scale processes while maintaining cell density, viability, and protein production.

  5. Enhance Your CHO-K1 GS Cell Culture Processes With A Next Generation Feed 7/21/2025

    Boost your CHO-K1 GS cell culture with a two-part feed system that delivers chemically defined, animal origin-free formulations for consistency and compliance.

  6. Scaling For Success: Preparing Your Cell Culture Workflow 7/21/2025

    Uncover how early planning of medium, feed systems, and manufacturing workflow can mitigate costs, reduce delays, and accelerate therapeutic delivery to patients.

  7. Consistent Improvement In CHO-K1 GS Performance With Efficient-Pro Feed 3 And Efficient-Pro Feed Enhancer 7/21/2025

    Optimize your CHO-K1 GS cell line with advanced chemically defined, animal origin-free feeds. Achieve higher titers and reliable product quality.

  8. Aiming For Success In Early mAb Process Development And Beyond 7/15/2025

    Developing a monoclonal antibody (mAb) requires strict quality compliance. Building on a strong foundation from the start with a quality by design (QbD) approach is key for success and minimizing variability.

  9. Enabling Development Of Scalable, Personalized Cell Therapies For Solid Tumor Treatments 6/16/2025

    Harnessing the body’s own immune system, researchers are developing personalized cell therapies to target solid tumors, using a patient’s unique mutations to create powerful, individualized treatments.

  10. Manufacturing CAR T Cell Therapies: Challenges, Insights And Solutions 6/16/2025

    Manufacturing patient-specific cell therapies is a complex, multi-step process. Addressing key hurdles in production time, scalability, and cost is crucial to making these vital treatments more accessible.